Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haibo Shen

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Redox Biology|August 26, 2023
LRRK2 aggravates kidney injury through promoting MFN2 degradation and abnormal mitochondrial integrityShun Zhang, Subo Qian, Hailong Liu, et al.
Frontiers in Oncology|November 17, 2022
Peripheral tuberculin purified protein derivative specific T cell immunoreactivity dynamics in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin instillation treatmentHuangqi Duan, Weimin Xia, Ding Xu, et al.
Oncotargets and Therapy|November 15, 2018
Clinical characterization of <i>ERBB2</i> exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patientsZhefeng Liu, Lin Wu, Jun Cao, et al.
Cancer Letters|January 12, 2025
RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIsXinjun Tang, Jie Hu, Renhua Guo, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world studyCheoklong Ng, Taile Jing, Shicheng Yu, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Redox Biology|August 26, 2023
LRRK2 aggravates kidney injury through promoting MFN2 degradation and abnormal mitochondrial integrityShun Zhang, Subo Qian, Hailong Liu, et al.
Frontiers in Oncology|November 17, 2022
Peripheral tuberculin purified protein derivative specific T cell immunoreactivity dynamics in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin instillation treatmentHuangqi Duan, Weimin Xia, Ding Xu, et al.
Oncotargets and Therapy|November 15, 2018
Clinical characterization of <i>ERBB2</i> exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patientsZhefeng Liu, Lin Wu, Jun Cao, et al.
Cancer Letters|January 12, 2025
RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIsXinjun Tang, Jie Hu, Renhua Guo, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world studyCheoklong Ng, Taile Jing, Shicheng Yu, et al.
Pageof 7